Abstract: Downstream regulatory element antagonist modulator (DREAM) protein is a 31 kDa Ca
Introduction
Downstream regulatory element (DRE) is a specific nucleotide sequence located nearby to the transcription start site of a gene promoter [1, 2] . DRE is a gene silencer that suppresses the transcription in an orientationindependent manner, when placed downstream from the transcription start site of a heterologous promoter [1, 3] . DREAM (downstream responsive element antagonist modulator), also termed KChIP-3 (potassium channel interacting protein-3) or calsenilin, is a multifunctional protein of the DREAM/KChIP subfamily of calcium sensors (KChIP-1 to -4) [1, 4] . DREAM, so far has mainly been known to be expressed in the nervous system in particular in sensory neurons where it has a predominantly nuclear localization. Blocking or unblocking of DRE element by binding or releasing of DREAM protein prevents or triggers the gene transcription [1, 5] . The DNA-binding properties of DREAM have been shown to play a role in the regulation of genes in the thyroid gland [6] , hematopoietic stem/ progenitor cells [7] , melatonin production in the pineal gland and the retina [8] , perception of pain [9] and to control learning and memory [10] .
DREAM contains four EF-hands that are helix-loophelix structural domains, which are present in many Ca 2+ -binding proteins and three of them have functional importance. In low Ca 2+ concentrations DREAM remains tightly bound to DRE and thus repress the transcription [4, 11, 12] . The Ca 2+ -DREAM interaction induces a conformational change of the protein that leads to its release from DRE. Tetrameric forms of DREAM have a much higher affinity to DRE than its monomeric form [4, 13] . Mutations within any of the three regulatory Ca 2+ -binding EF-hand motifs of DREAM [1, 12, 14] block the repression of c-fos gene due to retained DRE binding ability [4] . DREAM is found to interact with several different potassium channels and the shorter transcript calsenilin, and thought to play a major role in Alzheimer disease by its involvement in beta-amyloid protein processing [11, 15] . The human DREAM protein is composed of 284 residues [1] , where 256 residues of C-terminal are identical to calsenilin [16] . These 256 C-terminal residues of DREAM are sufficient for the Ca 2+ -regulation of transcription of 21 genes [2] . An et al. [11] have subsequently discovered a protein that may bind to α-subunits of Kv4 voltage-gated potassium channels and modulate the rapid inactivation of A-type outward current. This protein was called potassium channel interacting protein (KChIP) [11] . All four members of the DREAM/KChIP subfamily are closely related in terms of their structure and function [8] and they are co-expressed in different brain areas, as well as in other tissues including the immune system, thyroid gland, and reproductive system [17] .
Several pieces of evidences support the hypothesis for a direct link between DREAM and the regulation of insulin gene transcription via DRE of insulin gene promoter. First, there are high levels of DREAM transcript expression in endocrine tissues including in pancreatic b-cells [18] . The DREAM protein exerts the Ca 2+ -dependent regulation of prodynorphine expression of islet a-and b-cells and links pancreatic dynorphyne synthesis with enhanced glucagon secretion [18] . Calsenilin is also required for endocrine pancreas development in zebrafish [19] . Secondly, there is abundance of data on the interactions of DREAM with DRE of genes coding certain hormones and hormone receptors as thyroid stimulating hormone receptor [20] , glial fibrillary acidic protein gene [21, 22] , neuropeptide FF [23] calcitonin [24] , and thyreoglobulin [6] . The repression of transcription by DREAM bound to DNA is regulated not only by changes in intracellular concentrations of Ca 2+ but also through an interaction with nuclear effector proteins of cAMP-induced signaling. Mechanistically, DREAM functions as a negative regulator of the key neuronal transcription factor CREB in a Ca 2+ -dependent manner, and loss of DREAM facilitates CREB-dependent transcription during learning [25] .
In the current study we showed the expression and distribution of DREAM in human pancreatic islets and in rat insulinoma RIN-5F cells. Regulatory role for DREAM on insulin promoter activity and gene transcription was demonstrated through a newly discovered DRE element. 
Experimental Procedures

RIN-5F cells fractionation
Gentle homogenization of RIN-5F cells was applied to limit possible breakage of endosomes and other granular compartments such as neuroendocrine secretory granules. A 75% confluent cell layer was washed with PBS twice and then scraped into 2.5 ml PBS containing protease inhibitors (10 µg/ml aprotinin, 1 μg/ml Pepstatin, 10 μg/ml Leupeptin and 0.8 mM Pefabloc). The scraped cell suspension was then centrifuged on Eppendorf 5702 centrifuge for 5 min at 250xg at 4 o C. The cell pellet was resuspended in homogenization buffer (250 mM sucrose, 3 mM imidazol, pH 7.4, containing protease inhibitors as listed above). The cells were centrifuged again at 1500xg for 10 minutes at 4 o C. Cells were then resuspended in PBS containing 1 mM EDTA and with doubled concentrations of the protease inhibitors. The cell suspension was then drawn 5 times through a 22G needle attached to a 1 ml syringe and thus broken cells were centrifuged at 2000xg for 10 minutes at 4 o C to pellet unbroken cells and nuclei. The post-nuclear supernatant was then centrifuged for 30 minutes at 240000xg at 4 o C in a table-top Beckman centrifuge using the TLA-100 rotor. The supernatant was collected as cytosol and the pellet containing membranes and insulin secretory granules were resuspended in homogenization buffer. The protein content was determined in each fraction with a protein assay reagent (Pierce, IL, USA).
Western blot analysis
Endogenous DREAM was analyzed by loading an equal amount of protein (15 μg) of different cell fractions or neuroendocrine tissues and recombinant DREAM as control onto a 12% SDS-PAGE gel and run at 200 V in Tris-glycine or Tris-tricine buffer. The proteins were electrophoretically transferred onto nitrocellulose using Trans-Blot SD Semi-Dry Transfer Cell under constant current setting (100 mAmp/84 cm 2 ). Equal loading was ensured by Ponceau S staining. The membrane was blocked with 10% skim milk for 1 hour at room temperature. Then the membrane was incubated with anti-DREAM mAb for 2 hours, followed by peroxidase-conjugated goat anti-mouse secondary antibody (1:10000) for 45 minutes. Each incubation step was followed by two washes with PBS containing 0.1% Tween 20 for 10 minutes. Sites of specific Ab binding was visualized by developing the blot using BM chemoluminescent Western blotting kit (Roche Applied Science), and exposing the blot to Hyperfilm ECL (GE Healthcare). Membranes were stripped with stripping buffer (2% SDS, 100 mM Tris-HCl, 0.1% β-mercaptoethanol) for 45 min at 60°C and reprobed with β-actin Ab for loading control. The membranes were then exposed to x-ray films for various time intervals.
The images were captured with a GS-800 calibrated densitometer (Bio-Rad), and the ratio was quantified by densitometric analyses within the linear range of each captured signal.
Northern blot analysis
Total RNA was size fractionated on a 1.2% agarose gel, containing 0.7% formaldehyde, and transferred to Hybond-N membranes using 10x SSC buffer and a capillary blotting device. After fixing the RNA to the membrane by UV-cross linking (254 nm; 5 minutes) the blot was pre-hybridized in 12 ml warmed prehybridization solution for 5 hours at 42 o C in the cylinder (pre-hybridization solution: 50% formamid, 4xSSC, 1x Denhart's solution, 100 μg/ml denatured herring sperm DNA, 24 mM NaH 2 PO 4 (pH 6.5) and 0.84% glycine). Hybridizations were then performed in ULTRAhyb hybridization buffer (Life Technologies) consecutively using a DREAM and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes labeled with [a-32P] dCTP by using the random primer method (Megaprime, Amersham). After overnight hybridization blots were washed using NorthernMax High Stringency Wash solution 1 (2x SSC, 0.1% SDS; twice for 10 minutes at 45 o C), followed by NorthernMax Low Stringency Wash solution 2 (0.1x SSC, 0.1% SDS; twice for 10 minutes at 50 o C), and exposed for autoradiography to Kodak XAR5-Omat films at -80 o C.
Plasmids and transfections
The pcDNA3.1(+) expression vector containing DREAM or DREAM-triple mutant with artificial mutations in the EF-2, EF-3 and EF-4 hands [1] were gifts from Prof. Jose Ramon Naranjo and Prof. Britt Mellström (CNB University of Madrid, Spain). DREAM-coding insert was cloned into the pcDNA3.1(+) expression vector system as described before [25] . Successful cloning of DREAMexpression vector could be confirmed by restriction enzyme digest with following electrophoretic separation on a 1% agarose gel, and documentation of DREAMspecific insert as band under UV-light followed by DNA sequencing. In order to amplify the main regulatory part of the insulin promoter, PCR primers [forward 5' (GGGGACAGGGGTCC TGGGGACAGGGGTGTG), reverse 5' (TGGGGTCCAGCCACC CTGGAACCCTGAGCC) were designed. This part of the promoter contains 600 bp including the TATA box and the downstream cAMP responsive elements (CRE). The high fidelity PFu DNA polymerase (1 μl) and purified human genomic DNA (100 ng) were utilized as template. The thermal cycling parameters were set to 30 cycles at 94°C (60 s) for denaturation, 66°C (60 s) for annealing and 72°C (60 s) for synthesis. The initial denaturation step was set to 4 min at 94°C. The PCR product was then analyzed in a 1% agarose gel and an aliquot (10 μl) was treated with Taq DNA polymerase (1 μl) to attach an A overhang using 10x buffer (5 μl), and 10 mM ATP. The PCR-temperature was set to 72°C for 15 minutes. The product was then ligated into the pGEMT vector and amplified after transformation in E. coli. The insert was cut out using Eco R1 and overhangs were filled using T4 polymerase. 2 μl of Eco R1 cut insert were mixed with 10x buffer (5 μl), 100 μmol dNTPs, 1 μl T4 polymerase, and H 2 O to 50 μl, and incubated at 25°C for 20 minutes. The blunt ended gel purified fragment was then ligated into the Sma I cut pGL3 basic luciferase vector. The right orientation of the insulin promoter was tested by restriction enzyme digest and DNA sequencing.
RIN-5F rat insulinoma cells has been used for transfection and the cells were plated into 12 well plates in concentration 0.3x10 6 cells per well. After 24 hours the complete medium from the adherent cells was replaced by washing the cells with pre-warmed fetal calf serum-free RPMI1640 and the cells were co-transfected with 250 ng luciferase insulin promoter vector together with 100 ng of DREAM protein expression vector using Lipofectamin Plus (Invitrogen) as the transfection agent. The transfection ingredients were mixed as suggested in the manufacturer's manual. In short, 100 μl RPMI were mixed with 6 μl PLUS reagent and 250 ng reporter plasmid with 100 ng protein expression plasmid (DREAM or empty pcDNA3 as control) and incubated for 15 minutes at RT. Four hours after transfection medium was replaced with RPMI1640 (10 mM glucose) supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU/ml penicillin and 100 μg/ml streptomycin, and the cells were left to grow at 37 o C in a CO 2 incubator.
Luciferase assay
A pcDNA3.1(+) expression vector containing DREAM or DREAM-triple mutant with artificial mutations in the EF-2, EF-3 and EF-4 hands [1] were cotransfected together with pGL3 basic luciferase vector containing insulin promoter in front of the luciferase gene in RIN-5F cells. An empty pcDNA3.1(+) vector without DREAM insert cotransfected together with pGL3 basic luciferase vector was used as a control. Luciferase assays were performed 48 hours after transfection. After removing the culture medium the cells were washed by adding 2 ml DPBS and after removing it, 150 μl buffer was added into the well. The cells were detached. 20 μl of each RIN-5F cell lysate were used for measurement. The measurement was performed on a Berthold luminometer and the results are present in relative light units (RLU).
Electromobility shift assay (EMSA)
The 600 bp part of insulin promoter (from -488 bp to +112 bp) was synthesized on twenty sequential fragments of 30 bp long oligonucleotides. Each oligonucleotide fragment was labeled with [γ-32 P] ATP and T4 polynucleotide kinase. Approximately 100 000 cpm of the labeled oligonucleotide was incubated with 2-4 μg of the recombinant DREAM protein at room temperature for 20 min in the presence of the binding buffer, final volume 20 µl. The reaction mixture was then loaded onto a 5% non-denaturing polyacrylamid gel and run with 0.5x TBE buffer. After 2.5 hours the gel was dried and was exposed to an X-ray film at -80°C.
Statistical analysis
Statistical significance was determined by Student's t test for experiments with two groups or by performing an analysis of variance followed by the Fisher least significant difference test for experiments with more than two groups. A level of P<0.05 was considered statistically significant.
Results
DREAM mRNA expression in human tissues
Northern blot analysis of poly(A)-mRNA isolated from different human tissues yielded a 2.7 kb band representing DREAM mRNA. A strong expression of this mRNA was found in thyroid, testes and thymus and weaker in pancreas and stomach tissues ( Figure 1A) . A comparable mRNA loading of the samples was confirmed by a blot rehybridization with glyceraldehyde-3-phosphat dehydrogenase (GAPDH) cDNA ( Figure 1A , lower panel). Using Western blot we estimated the amount of DREAM protein in human pancreas and compared it with the levels in thalamus and pituitary gland by an anti-DREAM-specific mouse monoclonal antibody. There are abundant levels of DREAM protein in pancreatic and pituitary tissues; however no expression in thalamus was detected ( Figure 1B ).
DREAM expression in islets of Langerhans and RIN-5F insulinoma cells
Cryosections from post-mortem human pancreas samples of non-diabetic humans were stained with primary anti-DREAM mouse monoclonal antibody and visualized by TRITC-conjugated goat anti-mouse mAb ( Figure 2A , red color). The localization of the DREAM expression in the endocrine part of the pancreas was confirmed with specific anti-insulin FITC-labeled sheep Ab ( Figure 2B , green color). Thus DREAM staining is restricted to the islets of Langerhans, and expression is abundant mostly in the cytoplasm. The co-localization of DREAM and insulin is a proof for the expression of DREAM in the insulin secreting β-cells (Figure 2A,B) . The localization of DREAM in RIN-5F cells was detected by immunofluorescence staining and immunocytochemistry. Microscopic slides of fresh RIN-5F cells were incubated with anti-DREAM primary mAb, followed by TRITC-conjugated secondary goat anti-mouse Ab (red) ( Figure 2C ). PAP technique was also used for confirmation of DREAM specific localization (brawn) ( Figure 2D ). Both techniques visualized the sub-cellular localization of anti-DREAM mAb mostly in the cytoplasm and less in the nucleus of interphase cells ( Figure 2C,D) . In the stage of apoptosis, nuclear staining was absent ( Figure 2D , lower left corner, denoted with *) and cytoplasmic staining is weaker. In mitotic cells (metaphase) the DREAM staining was not observed ( Figure 2D , low in the middle, denoted with #).
DREAM localization in RIN-5F cell fractions
The localization of DREAM in different subcellular fractions of RIN-5F cells in culture was also studied. As a calcium-sensing protein, its activity is regulated by the changes in the levels of cytoplasmic calcium 
Figure 2. DREAM immunocytochemistry and immunostaining in human islets of Langerhans and RIN-5F cells. (A) Cryosections from human pancreas were incubated with anti-DREAM mAb (red). (B)
The same cryosections were also incubated with anti-Insulin polyclonal antibody (green). (C) Cytospin preparations of RIN-5F cells were stained with DREAM-specific mAb and TRITC-conjugated secondary goat anti-mouse mAb. Specific staining is detected at cytoplasmic and nuclear sites (magnification 1100x). (D) PAP-staining of cytospin preparations of RIN-5F cells reveals variable nuclear and cytoplasmic staining intensities of interphase cells (1200x). In the stage of apoptosis, nuclear staining is absent (lower left corner, cell denoted with *). In mitotic cells (metaphase) the DREAM staining was not present (low in the middle, cell denoted with #).
[Ca 2+ ] i . Treatment of RIN-5F cells with 25 mM KCl leads to a depolarization-induced Ca 2+ influx and rapid rise in [Ca 2+ ] i . One-and-a-half hour after stimulation the intact cells were lysated, fractionated and equal amounts of protein from each fraction was analyzed by Western blot. Three different fractions were used; nuclear, granular and cytosolic. The blot for DREAM protein demonstrates two well distinguished bands: a 30 kDa which represented its monomer form and it was exclusively localized in the granular fractions in both control (untreated) and KCl treated cells, as well as weak band in the nuclear fraction of KCl treated cells. Another band of 60 kDa is also detected, which represents the dimer form and was found in both nuclear and granular fractions. A change in band intensity occurred after elevation of intracellular calcium with 25 mM KCl, the protein shifted from dimer to monomer form. Monomeric form of DREAM was highly elevated in the presence of KCl in the granular (membrane) fraction ( Figure 3A ). In the same time dimeric form decreased in both nuclear and granular fractions after treatment with 25 mM KCl. There were no detectable levels of DREAM in the cytosolic fractions in both, untreated controls and KCl incubated cells. To compare the levels of DREAM protein in the different fractions in treated and untreated cells we did densitometric analysis of x-ray films of the respective experimental groups. In the nuclear and granular fractions the levels of dimeric form of DREAM in 25 mM KCl treated cells were less than half of the respective controls. In contrast, in the granular fraction the monomeric form level increased 4.5 fold compared to the control ( Figure 3B ).
Measurement of the insulin gene transcription in RIN-5F cells
A pcDNA3.1(+) expression vector containing DREAM cDNA was co-transfected together with a pGL3-based luciferase vector containing insulin promoter in front of the luciferase gene in RIN-5F cells. In this reporter construct luciferase activity was controlled by the 600 base pairs of the human insulin promoter (-488/+112 nucleotides). This promoter region contains several regulatory elements including an NRE/Z motif and the Egr1/Sp1 site, as well as all four CRE/CaRE motifs. Cells containing empty pcDNA3.1(+) vector without DREAM insert, co-transfected together with pGL3-based luciferase vector were used as control. Two days after transfection the cells were harvested, lysed and the amount of the produced luciferase was measured by luminometer. The transfection assay showed inhibitory effect of DREAM on the promoter activity and respectively the transcription of insulin gene (Figure 4) . 
EMSA of human insulin promoter oligonucleotides and recombinant human DREAM
The inhibitory effect of DREAM on the insulin gene transcription suggests that the former interacts with the insulin promoter. This hypothesis was studied by using a 600 bp sequence of the main regulatory part of the promoter (-488/+112 nucleotides) with electrophoretic mobility shift assay (EMSA). This long sequence was cleaved in twenty consecutive sequences of 30 bp each and they were analyzed individually for band retardation. Each double-stranded oligonucleotide was labeled separately with 32 P-ATP and incubated with recombinant DREAM protein. DREAM-specific interaction was detected when recombinant DREAM and oligonucleotide 19 (GGT CTG TTC CAA GGG CCT TTG CGT CAG GTG) were used ( Figure 5, lane 1, left) . All other oligonucleotides did not show any specific band retardation and a representative sample is shown ( Figure 5, lane 2, right) .
Discussion
Our results, as well as the previously published data [18] , show that DREAM is expressed and is present in human pancreatic β-cells. Here we find that DREAM is a direct regulator of insulin promoter activity.
The reports for DREAM binding to the DRE of prodynorphin, c-fos [1] as well as the detection of DREAM in the nuclear fraction of insulinoma cells in this study have encouraged us to test the direct effect of DREAM on insulin gene transcription. We have used plasmid constructs with the human insulin promoter driving the expression of a firefly luciferase gene. Overexpression of DREAM in co-transfected with reporter plasmid RIN-5F cells causes inhibition of insulin promoter activity. These data confirm the importance of DREAM-dependent regulation of transcription.
Our experiments have shown that DREAM is localized in different cellular fractions of RIN-5F cells. A depolarization-induced increase of [Ca 2+ ] i by KCl in RIN-5F cells leads to a decrease of nuclear and granular dimeric form and a corresponding increase of monomeric DREAM in the granular fraction. This suggests that DREAM disconnects from DRE binding sites in the nucleus in a Ca 2+ -dependent manner and dissociates into free monomers. RIN-5F cells and pancreatic β cells express voltage-gated calcium channels (VGCC). In addition, there is sufficient data showing that TRP channels, which are abundantly expressed on β cells, might also play a significant role in the regulation of insulin release from pancreatic β cells [26] . KCl treatment activates both VGCC and TRP as well as mobilization of intracellular Ca 2+ stores and Ca 2+ release regulates a multitude of cellular functions, but the role of this release remains incompletely understood. It is possible that both, the activation of different calcium channels and calcium release from intracellular stores contributes to the regulation of DREAM activity. The repression of gene transcription by DREAM-DRE promoter element interaction is abolished when intracellular free Ca 2+ is elevated [1, 2] . Using transgenic mice (TgDREAM) overexpressing a Ca 2+ -and cAMP-insensitive DREAM mutant it was found that NMDA receptor-mediated synaptic transmission and plasticity was impaired in TgDREAM mice [27, 28] . Zaidi et al. [29] have found that calsenilin traslocates from the cytoplasm to the nucleus when cells were treated with pharmacological agents that directly manipulate the levels of intracellular calcium (caffeine and the calcium ionophore A23187), suggesting that the increased levels of calsenilin in the nucleus are mediated by changes in the intracellular calcium concentration [29] . These findings together with our data indicate that DREAM translocation depends on the level of intracellular free Ca 2+ . In b-cells of adult humans a variety of mechanisms simultaneously controls pancreatic insulin gene expression [30] . These include both positive and negative influences of signaling pathways: the crosstalk between activating and repressing transcription factors, as well as reversible regulatory phosphorylations and overlapping activity of regulatory elements, e.g. A3 and CRE. The transcriptional regulatory sequences are believed to be located mainly within the 300-400 bp upstream of the site of initiation of insulin gene [31] but some regulatory motifs are also localized and operate downstream from the transcription start site [30] . Therefore, in our EMSA experiments we have studied a 600 bp sequence of the regulatory part of insulin promoter (from -488 bp to 112 bp downstream). An oligonucleotide sequence 19 (GGT CTG TTC CAA GGG CCT TTG CGT CAG GTG) has been identified as the most probable place of the DREAM-insulin promoter interaction. This 30bp sequence is located between +52 and +81 of the promoter and, therefore, includes the 4 th CRE (CRE4) that starts at +61 and has the TGCGTCAG sequence [30] . The DRE alone consists of 14 bp and the sequence GTCA forms the central core of the DRE site [12] . In our case such sequence is available in 19 th oligonucleotide and it is a part of CRE4. Although none of the CRE sites contain the consensus CRE sequence of TGACGTCA, mutagenesis experiments have shown that all CRE promoter elements are transcriptionally active -(CRE4, as well as CRE1) at -210, CRE2 at -183 and CRE3 at +18 [32] . Ledo et al. [25] have shown that in the absence of calcium, DREAM binds to CREB, impairs the recruitment of CBP by phospho-CREB, and blocks the CBP-mediated activation at CRE sites in a Ca 2+ -dependent manner [25] . Thus, the phosphorylationindependent regulation of CREB activity is a Ca 2+ -dependent interaction between DREAM and CREB or phospho-CREB that regulates the accessibility of CBP to the KID domain in CREB, and so compromises CRE transcription. Thus, Ca 2+ -dependent interactions between DREAM and CREB represent a possible cross-talk between cAMP and Ca 2+ signaling pathways in the cell nucleus [25] . However, the role of DREAM-CRE4 promoter element interaction and the relative contribution of DREAM in insulin promoter regulation [33] remain unsolved, and require further studies.
Lusin et al. [34] reported that the four EF-hands of DREAM are located at the C-terminal part of the molecule between residues 78-256. The first and second EF-hands form a hydrophobic groove on the protein surface. The leucine residues in the formed hydrophobic groove can form intermolecular contacts with other leucine residues. One side of the protein surface consists of clustered positively charged side chains of Arg and Lys (Lys87, Lys90, Lys91, Arg98, Lys101, Arg160, and Lys166). These chains may mediate electrostatic interactions with DNA [4] . We suggest that certain SNPs, which lead to amino acid exchange, may influence the DREAM-DRE binding and thus to repress more tightly the insulin promoter activity, while also modulating Ca 2+ sensitivity. Moreover, the exchange of Arg to Gln at position 98 affects the Arg-Lys cluster [34] , which mediates the DREAM-DNA interaction. It has already been shown that DREAM regulates T-lymphocyte proliferation when it binds to the promoters and represses the transcription of IL-2, IL-4, and IF-gamma in a Ca 2+ -dependent manner [17] . In this connection, it can be hypothesized that some SNP's in DREAM gene might be involved in autoimmune destruction of β-pancreatic cells and type-1 diabetes. Insulin is secreted in pulses in synchrony with Ca 2+ pulses [35] and DREAM has been reported to play an important role in pulsating calcium release in gonadotropin-releasing hormone expression [36] .
It will be interesting to look for polymorphisms in DREAM gene that lead to different forms of DREAM.
Some of these different DREAM forms will have nonfunctional EF-hands as a result of point mutations, and will be less sensitive to the changes of intracellular calcium levels. Such forms may be tightly bind to the DRE promoter element and can interfere and eventually prevent CREB induced gene transcription, since CRE sequence is located inside the DRE element. Future investigation in patients with diabetes mellitus for DREAM polymorphisms could clarify the role of DREAM protein in insulin gene transcription and processing in diabetes mellitus.
In conclusion, our work identifies the DRE sequence in the insulin promoter and provides evidence that DREAM is a direct repressor of insulin transcription. Future studies remain to elucidate the mechanism for interactions between DREAM and CREB and whether complexes formed between them are required for the regulation of insulin gene expression.
